Secukinumab
- Generic Name
- Secukinumab
- Brand Names
- Cosentyx
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229022-83-6
- Unique Ingredient Identifier
- DLG4EML025
- Background
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Fo...
- Indication
Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy. In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.
...
- Associated Conditions
- Enthesitis Related Arthritis (ERA), Juvenile Idiopathic Arthritis (JIA), Juvenile psoriatic arthritis, Non-radiographic Axial Spondyloarthritis, Severe Plaque psoriasis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Plaque psoriasis
- Associated Therapies
- -
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT03031782
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 196
- Registration Number
- NCT03020199
- Locations
- 🇬🇧
Novartis Investigative Site, Salford, United Kingdom
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 458
- Registration Number
- NCT02896127
- Locations
- 🇬🇧
Novartis Investigative Site, Wigan, United Kingdom
Effect of Secukinumab in the Treatment of Psoriatic Arthritis
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 30
- Registration Number
- NCT02854163
- Locations
- 🇬🇧
Aintree University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1114
- Registration Number
- NCT02826603
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Anti-IL-17 a New Treatment for Contact Dermatititis
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Tanja Todberg, MD
- Target Recruit Count
- 20
- Registration Number
- NCT02778711
- Locations
- 🇩🇰
Department of Dermato-Allergology, Hellerup, Denmark
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1660
- Registration Number
- NCT02752776
- Locations
- 🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom
Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 8
- Registration Number
- NCT02733094
- Locations
- 🇩🇪
Technical University of Munich, Munich, Germany
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 555
- Registration Number
- NCT02696031
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
A Study of Secukinumab for the Treatment of Alopecia Areata
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 11
- Registration Number
- NCT02599129
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.